The cognitive profile of aripiprazole differs from that of other atypical antipsychotics in schizophrenia patients

Journal of Psychiatric Research

Volumn 46, Issue 6, 2012, Pages 757-761

  Hori, Hikaru ^a   Yoshimura, Reiji ^a   Katsuki, Asuka ^a   Hayashi, Kenji ^a   Ikenouchi Sugita, Atsuko ^a   Umene Nakano, Wakako ^a   Nakamura, Jun ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

Aripiprazole; BACS; Cognitive function; Dosage; Olanzapine; Risperidone; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; BRIEF ASSESSMENT OF COGNITION IN SCHIZOPHRENIA; BRIEF PSYCHIATRIC RATING SCALE; COGNITIVE DEFECT; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; LEARNING; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT; SCHIZOPHRENIA;

EID: 84861220889     PISSN: 00223956     EISSN: 18791379     Source Type: Journal    
DOI: 10.1016/j.jpsychires.2012.02.013     Document Type: Article

References (40)

1. American Psychiatric Association DSM-IV: diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, Washington, DC. 4th ed.
2. Alemen A., Agrawal N., Morgan K.D., David A.S. Insight in psychosis and neuropsychological function: meta-analysis. British Journal of Psychiatry 2006, 189:204-212.
3. Artigas F. The prefrontal cortex: a target for antipsychotic drugs. Acta Psychiatrica Scandinavica 2010, 121(1):11-21.
4. Bowie C.R., Harvey P.D. Cognition in schizophrenia: implications, and functional importance. Psychiatric Clinics North America 2005, 28:613-633.
5. Bronson B.D., Lindenmayer J.P. Adverse effects of high-dose olanzapine in treatment-refractory schizophrenia. Journal of Clinical Psychopharmacology 2000, 20(3):382-384.
6. Crespo-Facorro B., Rodriguez-Sanchez J.M., Perez-Iglesias R., Mata I., Avesa R., Ramirez-Bonilla M., et al. Neurocognitive effectiveness of haloperidol, risperidone, and olanzapine in first-episode psychosis: a randomized, controlled 1-year follow-up comparison. Journal of Clinical Psychiatry 2009, 70(5):719-729.
7. Cuesta M.J., Jalon E.G., Campos M.S., Peralta V. Cognitive effectiveness of olanzapine and risperidone in first-episode psychosis. The British Journal of Psychiatry 2009, 194(5):439-445.
8. Davidson M., Galderisi S., Weiser M., Werbeloff N., Fleischhacker W.W., Keefe R.S., et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). American Journal of Psychiatry 2009, 166(6):675-682.
9. First M.B., Spitzer R.L., Gibbon M., Williams B.W. Structured clinical interview for DSM-IV axis I disorders, patient edition (SCID-P), version 2 1995, New York State Psychiatric Institute, Biometrics Research, New York.
10. Forbes N.F., Carrick L.A., McIntosh A.M., Lawrie S.M. Working memory in schizophrenia: a meta-analysis. Psychological Medicine 2008, 39(6):889-905.
11. Gerlach J. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Annals of Clinical Psychiatry 2002, 14(1):47-57.
12. Glahn D.C., Ragland J.D., Abramoff A., Barrett J., Laired A.R., Bearden C.E., et al. Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Human Brain Mapping 2005, 25(1):60-69.
13. Green M.F., Barnes T.R., Danion J.M., Gallhofer B., Meltzer H.Y., Pantelis C. The FOCIS international survey on psychiatrists' opinions on cognition in schizophrenia. Schizophrenia Research 2005, 74(2-3):253-261.
14. Grunder G., Carlsson A., Wong D.F. Mechanism of new antipsychotic medications: occupancy is not just antagonism. Archives of General Psychiatry 2003, 60(10):974-977.
15. Hamamura T., Harada T. Unique pharmacological profile of aripiprazole as the phasic component buster. Psychopharmacology 2007, 191(3):741-743.
16. Harvey P.D., Keefe R.S. Studies of cognitive change in patients with schizophrenia following novel antipsychotic treatment. American Journal of Psychiatry 2001, 158(2):176-184.
17. Heinrichs R.W., Zakzanis K.K. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology 1998, 12:426-445.
18. Heinz A., Romero B., Gallinat J., Juckel G., Weinberger D.R. Molecular brain imaging and the neurobiology and genetics of schizophrenia. Pharmacopsychiatry 2003, 36(3):152-157.
19. Hofer A., Baumgartner S., Bodner T., Edlinger M., Hummer M., Kemmler G., et al. Patient outcomes in schizophrenia II: the impact of cognition. European Psychiatry 2005, 20(5-6):395-402.
20. Hori H., Noguchi H., Hashimoto R., Nakabayashi T., Omori M., Takahashi S., et al. Antipsychotic medication and cognitive function in schizophrenia. Schizophrenia Research 2006, 86(1-3):138-146.
21. Kaneda Y., Sumiyoshi T., Keefe R., Ishimoto Y., Numata S., Ohmori T. Brief assessment of cognition in schizophrenia: validation of the Japanese version. Psychiatry and Clinical Neurosciences 2007, 61(6):602-609.
22. Kaneda Y., Sumiyoshi T., Nakagome K., Numata S., Tanaka T., Ueoka Y., et al. The brief assessment of cognition in schizophrenia Japanese version (BACS-J). Seishinigaku 2008, 50(9):913-917. [in Japanese].
23. Kawai N., Yamakawa Y., Baba A., Nemoto K., Tachikawa H., Hori T., et al. High-dose of multiple antipsychotics and cognitive function in schizophrenia: the effect of dose-reduction. Progress in Neuro-psychopharmacology and Biological Psychiatry 2006, 30(6):1009-1014.
24. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (PANSS) manual. Schizophrenia Bulletin 1987, 13(2):261-276.
25. Kishi T., Moriwaki M., Kawashima K., Okochi T., Fukuo Y., Kitajima T., et al. Investigation of clinical factors influencing cognitive function in Japanese schizophrenia. Neuroscience Research 2010, 66(4):340-344.
26. Krausz M., Mortiz S., Lambert M., Naber D. Dosage of conventional neuroleptic medication and subjective cognitive functioning in schizophrenia. International Clinical Psychopharmacology 2000, 15(2):77-81.
27. Lee J., Park S. Working memory impairments in schizophrenia: a meta-analysis. Journal of Abnormal Psychology 2005, 114(4):599-611.
28. Leucht S., Komossa K., Rummel-Kluge C., Corves C., Hunger H., Schmid F., et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. American Journal of Psychiatry 2009, 166(2):152-163.
29. Mace S., Taylor D. Aripiprazole: dose-response relationship in schizophrenia and schizoaffective disorder. CNS Drugs 2009, 23(9):773-780.
30. McClure M.M., Harvey P.D., Goodman M., Triebwasser J., New A., Koenigsberg H.W., et al. Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum. Neuropsychopharmacology 2010, 35(6):1356-1362.
31. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999, 21(Suppl. 2):106S-115S.
32. Mishara A.L., Goldberg T.E. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biological Psychiatry 2004, 55(10):1013-1022.
33. Moritz S., Woodward T.S., Krausz M., Naber D. Relationship between neuroleptic dosage and subjective cognitive dysfunction in schizophrenic patients treated with either conventional or atypical neuroleptic medication. International Clinical Psychopharmacology 2002, 17(1):41-44. PERSIST Study Group.
34. Passingham D., Sakai K. The prefrontal cortex and working memory: physiology and brain imaging. Current Opinion in Neurobiology 2004, 14(2):163-168.
35. Rummel-Kluge C., Komossa K., Schwarz S., Hunger H., Schmid F., Kissling W., et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophrenia Bulletin 2010.
36. Sparshatt A., Taylor D., Patel M.X., Kapur S. A systematic review of aripiprazole-dose, plasma concentration, receptor occupancy, and response: implications for therapeutic drug monitoring. Journal of Clinical Psychiatry 2010, 71(11):1447-1456.
37. Svensson T.H. Alpha-adrenoceptor modulation hypothesis of antipsychotic atypicality. Progress in Neuro-psychopharmacology and Biological Psychiatry 2003, 27(7):1145-1158.
38. Sweeny J.A., Kelip J.G., Haas G.L., Hill J., Weiden P.J. Relationships between medication treatments and neuropsychological test performance in schizophrenia. Psychiatry Research 1991, 37(3):297-308.
39. Takahashi H., Kato M., Hayashi M., Okubo Y., Takano A., Ito H., et al. Memory and frontal lobe functions: possible relations with dopamine D2 receptors in the hippocampus. Neuroimage 2007, 34(4):1643-1649.
40. Thornton A.E., Van Snellenberg J.X., Sepehry A.A., Honer W. The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review. Journal of Psychopharmacology 2006, 20(3):335-346.